35-8800

antibody from Invitrogen Antibodies

Targeting: CXCR4 CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R

Provider product page for 35-8800

Western blot

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [25]
Comments [0]
Validations
Flow cytometry [1]
Other assay [8]

Submit

Product number: 35-8800 - Provider product page
Provider: Invitrogen Antibodies
Product name: CXCR4 Monoclonal Antibody (12G5)
Antibody type: Monoclonal
Antigen: Other
Description: By Western blot, 35-8800 detects a band at ~60kD, which likely represents an isoform or post-translationally modified form of CXCR4, many of which have been described in the literature.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: 12G5
Vial size: 100 µg
Concentration: 0.5 mg/mL
Storage: -20°C

CXCR4 protein structure - 35-8800 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Immunohistochemical staining of each CSC marker in pancreatic adenocarcinoma. The arrows indicate strong staining intensity of EpCAM (A) , CD24 (B) , CD44 (C) , CD133 (D) , CXCR4 (E) and ALDH1 (F) . Scale bar, 100 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Representative images of particular proteins' expression (magnification x200). a CK 5/6, b CXCR4, c CaSR, d COX2, e OPN n , f OPN cyt , g PTHrPR1

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Expression of metastatic markers in invasive lobular breast cancer (LBC) cells. (a) Co-expression of osteopontin (green) in invasive lobular carcinoma (ILC) cells positive for vimentin (red). Asterisks mark in situ lesions. (b) LBC cells with activated c-Src (green) coexpress the bone metastatic marker osteopontin (red). (c) Cxcr4, a marker for lymph node metastasis, was weakly expressed in the in situ lesions (left) and strongly expressed in the vast majority of invasive cancer cells (middle and right).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 B cell viability is regulated by hCXCR4 expression under hypoxic condition. A , B WiL2-NS cells were incubated for 12, 24, 36 h under normoxic or hypoxic conditions. Cell viability was assessed by using trypan blue exclusion assay ( A ) and cell number was calculated ( B ). C - E WiL2-NS cells were transfected with pEZX-PG02-hCXCR4-gaussia luciferase (Gluc) plasmid DNA using Viafect(tm). After 30 h transfection, WiL2-NS cells were incubated with hypoxia and Gluc activity of hCXCR4 promoter (pmt) was measured by using luminometer ( C ). RNA was extracted by using Nucleozol. mRNA of hCXCR4 was measured by RT-PCR ( D ) or real-time qPCR ( E ). F , G Mutant promoter to hCXCR4 was prepared from wild type promoter ( F ). WiL2-NS cells were transfected with wild-type or mutant-type pEZx-PG02-hCXCR4-Gluc promoter plasmid DNA. 30 h after transfection, WiL2-NS cells were incubated under hypoxic condition and Gluc activity was measured by using luminometer ( G ). H , I Cells were transfected with CXCR4-siRNA under normoxic condition. RNA was extracted by using Nucleozol. mRNA of hCXCR4 was measured by RT-PCR ( H , top). Cell lysates were prepared and the level of each protein was measured by western blot analysis ( H , bottom). Cell viability under hypoxic conditions was assessed by trypan blue exclusion assay ( I ). Each experiment was performed at least five times. Data in bar or line graphs stands for the means +- SD. ** p < 0.01; significantly different from control group und

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 In vivo biodistribution and anti-tumor effect of the NN/NKEXO cocktail. ( a ) Bioluminescence (Luc) and miRNA fluorescence (Cy5) images of major organs of the NOD/SCID mice bearing systemic CHLA-255-luc tumors 6 h after intravenous (i.v.) injection of Cy5-let-7a, Cy5-let-7a-dendrimers and Cy5-labeled NN/NKEXO cocktail: 1) Heart; 2) lung; 3) liver; 4) kidney; 5) spleen and 6) tumor. ( b ) Bioluminescence (Luc) and fluorescence images of major organs 6 h after i.v. injection of DiR-labeled NN/NKEXO cocktail made of 5.28 µg of let-7a and 100 mug of NKEXOs. ( c ) In vivo two-photon excitation fluorescence images of the CHLA-255 luc subcutaneous tumor model 20 min after i.v. injection of 400 muL dual fluorescently labeled NN/NKEXO cocktail made of 5.28 µg of let-7a and 100 mug of NKEXOs. ( d ) Expression of functional proteins (CD47 and CXCR4) was confirmed by WB. ( e ) Experimental protocol for CHLA-255 luc -NOD/SCID mice shown in ( f ). ( f ) Bioluminescence imaging (BLI) performed in CHLA-255 luc -NOD/SCID mice treated with different cocktail formulations at let-7a dose of 5.28 µg and NKEXO dose of 100 µg ( n = 3). ( g ) Quantification of BLI results. Each bar represents mean +- SD of three replicates. * p < 0.05 and ** p < 0.001.